ArticleMedComm2026
METTL1-Mediated N
Abstract read
In one paragraph
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- tRNA methylation: functional insights and epitranscriptomic regulation.Cell communication and signaling : CCS · 2026Review
- Sevoflurane ameliorates cerebral ischemia-reperfusion injury by modulating mitochondrial dynamics and attenuating apoptosis via Shh-YAP1 signaling pathway.Molecular brain · 2026Article
- METTL1-Mediated NMedComm · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Yue ZhangKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Mingyang LengKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Ruonan WangKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Xinyuan TangKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Zhenlu CaiKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Liang WangKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Xiaoqi ShaoKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Hongtao DiaoKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Qinqiang LongKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Xu LiKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Yingzi WuKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Yuan JiangDepartment of Cardiology Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Haifeng ZhangDepartment of Cardiology Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Haihai LiangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin China.
Jiao GuoKey Laboratory of Glucolipid Metabolic Disorder Ministry of Education of China Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease is one of the diseases with the highest morbidity and mortality in the world. The N
Indexed as
m7G tRNA modificationMETTL1mitochondrial energy metabolismmyocardial ischemia/reperfusion injury
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.